Organon and Entelos extend research agreement
Organon, the human healthcare business unit of Akzo Nobel and Entelos Inc. announced a two-year extension of their ongoing rheumatoid arthritis (RA) collaboration. Financial terms were not disclosed.
"We are very pleased to continue our partnership with Organon," stated James Karis, president and CEO of Entelos. "Organon was one of the first companies to recognize the potential impact of Entelos' biosimulation capability and therapeutic expertise. We believe that our ability to consistently deliver value to our customers improves their prospects of developing drugs which directly benefit patients suffering from serious complex diseases such as RA."
"The collaboration with Entelos has generated candidate targets and biomarkers which will be pursued under the extension of our collaboration", said David Nicholson, executive vice president, Research & Development at Organon. "We continue to seek partnerships that move us to the forefront of RA research and development and look forward to the future benefits of Entelos' in silico approach in target and biomarker validation."
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.